XOMA (XOMA) News Today → A once-in-a-century investment opportunity (From Stansberry Research) (Ad) Free XOMA Stock Alerts $25.51 -0.15 (-0.58%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 4:26 AM | americanbankingnews.comXOMA (NASDAQ:XOMA) Share Price Crosses Above 200 Day Moving Average of $21.30May 14, 2024 | globenewswire.comXOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQMay 10, 2024 | americanbankingnews.comXOMA (NASDAQ:XOMA) Stock Crosses Above 200 Day Moving Average of $20.97May 9, 2024 | investorplace.comXOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comXOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesMay 2, 2024 | marketbeat.comQ1 2024 Earnings Forecast for XOMA Co. Issued By Leerink Partnrs (NASDAQ:XOMA)XOMA Co. (NASDAQ:XOMA - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for XOMA in a report issued on Monday, April 29th. Leerink Partnrs analyst D. Risinger anticipates that the biotechnology company will post earnings of ($0.85) per sMay 2, 2024 | marketbeat.comXOMA (NASDAQ:XOMA) Rating Reiterated by Leerink PartnrsLeerink Partnrs reiterated an "outperform" rating on shares of XOMA in a research note on Monday.May 1, 2024 | marketbeat.comXOMA's (XOMA) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $74.00 price target on shares of XOMA in a research note on Wednesday.April 29, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For XOMAApril 29, 2024 | marketbeat.comXOMA (NASDAQ:XOMA) Receives New Coverage from Analysts at SVB LeerinkSVB Leerink started coverage on XOMA in a research report on Monday. They set an "outperform" rating and a $40.00 price objective on the stock.April 25, 2024 | finance.yahoo.comXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)April 25, 2024 | marketbeat.comXOMA's (XOMA) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $74.00 price objective on shares of XOMA in a research report on Thursday.April 25, 2024 | globenewswire.comXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)April 24, 2024 | prnewswire.comActym Therapeutics Appoints Thomas Smart as CEOApril 20, 2024 | finance.yahoo.comXOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five yearsApril 9, 2024 | marketbeat.comXOMA Co. (NASDAQ:XOMA) Shares Sold by Stonepine Capital Management LLCStonepine Capital Management LLC lessened its holdings in XOMA Co. (NASDAQ:XOMA - Free Report) by 42.7% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 250,000 shares of the biotechnology company's stock after sellingApril 3, 2024 | globenewswire.comXOMA Corporation Announces Closing of Tender OfferMarch 21, 2024 | globenewswire.comXOMA Declares Quarterly Preferred Stock DividendsMarch 19, 2024 | globenewswire.comXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.March 13, 2024 | businesswire.comKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEMarch 8, 2024 | investorplace.comXOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023March 8, 2024 | finance.yahoo.comXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueMarch 8, 2024 | globenewswire.comXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueFebruary 28, 2024 | globenewswire.comXOMA to Present at Upcoming Investor Conferences in MarchFebruary 19, 2024 | businesswire.comKINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEFebruary 18, 2024 | msn.comCompare with Maple Leaf Green World Inc (4HV0)February 17, 2024 | finance.yahoo.comXOMA Mar 2024 20.000 putFebruary 17, 2024 | finance.yahoo.comXOMA Jun 2024 25.000 callFebruary 16, 2024 | marketbeat.comXOMA's (XOMA) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $74.00 price target on shares of XOMA in a report on Friday.February 16, 2024 | benzinga.comBiotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate BiopharmaFebruary 16, 2024 | marketwatch.comXOMA Agrees to Acquire Kinnate BiopharmaFebruary 16, 2024 | finance.yahoo.comXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightFebruary 16, 2024 | finance.yahoo.comXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightFebruary 16, 2024 | globenewswire.comXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightFebruary 16, 2024 | marketbeat.comTrading was temporarily halted for "XOMA" at 07:02 AM with a stated reason of "News pending."February 14, 2024 | marketbeat.comXOMA Co. (NASDAQ:XOMA) Short Interest Up 13.1% in JanuaryXOMA Co. (NASDAQ:XOMA - Get Free Report) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 320,700 shares, a growth of 13.1% from the January 15th total of 283,600 shares. Based on an average trading volume of 26,500 shares, the short-interest ratio is presently 12.1 days.February 8, 2024 | marketbeat.comXOMA (NASDAQ:XOMA) Shares Cross Above 200-Day Moving Average of $16.86XOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving Average of $16.86January 20, 2024 | finance.yahoo.comWith 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investorsJanuary 11, 2024 | markets.businessinsider.comXOMA To Pay $1 Mln Milestone To LadRx As FDA Accepts Zevra's Arimoclomol NDA For NPCJanuary 11, 2024 | tmcnet.comFDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxJanuary 11, 2024 | marketwatch.comXoma to Make $1M Milestone Payment to LadRx After FDA Accepts Zevra Application for ArimoclomolJanuary 11, 2024 | markets.businessinsider.comXoma To Make $1 Mln Milestone Payment To LadRx After FDA Accepts Zevra's NDA For ArimoclomolJanuary 11, 2024 | finance.yahoo.comFDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxJanuary 8, 2024 | seekingalpha.comXoma appoints Owen Hughes as CEO, Jack Wyszomierski as chairmanJanuary 6, 2024 | wsj.comXOMA Corp. Dep. Pfd. (Rep. 8.375% Cum. Pfd. Series B)January 2, 2024 | msn.comXOMA announces stock repurchase program of up to $50MJanuary 2, 2024 | marketwatch.comXOMA Sets Initial Stock Buyback of $50 MillionJanuary 2, 2024 | markets.businessinsider.comXOMA To Repurchase Up To $50 Mln Of SharesJanuary 2, 2024 | finance.yahoo.comXOMA Announces Stock Repurchase Program of up to $50 MillionDecember 29, 2023 | seekingalpha.comXOMA Preferreds: I Upped My Rating On One Preferred Stock To A Buy Get XOMA News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. XOMA Media Mentions By Week XOMA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XOMA News Sentiment▼-0.280.51▲Average Medical News Sentiment XOMA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XOMA Articles This Week▼21▲XOMA Articles Average Week Get XOMA News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Verastem News Vanda Pharmaceuticals News Emergent BioSolutions News Merrimack Pharmaceuticals News Rigel Pharmaceuticals News Regulus Therapeutics News Syros Pharmaceuticals News Lexicon Pharmaceuticals News Cue Biopharma News OPKO Health News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XOMA) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
